Table 2: Colorectal
Cancer Screening Tests.
Screening modality |
Sensitivity |
Specificity |
Cost per test US dollars |
Serious
Complications |
|
Advanced Adenoma |
Cancer |
||||
FOBT |
17.7%-49.4% |
50.0-87.0% |
90.0-95.0% |
$8-$23 |
NS |
FIT |
16.0-48.0% |
71.0-87.0% |
92.5-98.0% |
$13-$40 |
NS |
sDNA |
42.4-44.6% |
92.3-92.6% |
83.8-89.8% |
$400-$800 |
NS |
CT
Colonography |
83.3%-93.0% |
93.3%-96.5% |
89.0%-96.5% |
$400-$800 |
0-6/10,000 |
Sigmoidoscopy |
71.3%-85.6% |
58.3%-75.0% |
89.0-95.0% |
$169-$507 |
3.4/10,000 |
Colonoscopy |
85.0%-95.0% |
92.0%-97.0% |
90.0-100% |
$645-$1013 |
25/10,000 |
FOBT:
high sensitivity guiac fecal occult blood test (Hemoccult Sensa); FIT: fecal
immunochemical test; sDNA: multi-target stool DNA test (Cologuard); DCBE:
double-contrast barium enema; CT: computed tomography; Advanced adenoma:
adenomas ≥ 10 mm.
Serious
complications: deaths or hospitalizations from perforation, major bleeding,
diverticulitis, severe abdominal pain, and cardiovascular events.
NS:
estimated to be non-significant although evidence lacking